Executive Director
MedImmune/AstraZeneca
David Robbins is an Executive Director in Biopharmaceutical Development at MedImmune/AstraZeneca, leading late-stage purification development for 20 years. David has overseen downstream development of more than two dozen monoclonal antibodies and other biopharmaceutical products. David has been a leader at AZ in developing strategies for Quality by Design, and agile and accelerated development. In recent years, David led the process validation strategy for global development of Vaxzevria COVID-019 Vaccine and contributed to development and regulatory strategy for the Evusheld antibody cocktail for pre-exposure prophylaxis of COVID-19. David is currently leading the CMC team developing AZD3152 as a next generation Evusheld.